Online inquiry

IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4115MR)

This product GTTS-WQ4115MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ICAM1 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000201.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3383
UniProt ID P05362
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4115MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10158MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ15283MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Theraloc
GTTS-WQ1710MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ2758MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG162
GTTS-WQ8991MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ2358MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AME-133v
GTTS-WQ720MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA A-623
GTTS-WQ9739MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JR-141
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW